Examination of the potential interaction between ketoconazole (Nizoral) and oral contraceptives with special regard to products of low hormone content (Rigevidon, anteovin).
I
I
Kovács
P
P
Somos
M
M
Hámori
D000293:Adolescent; D000328:Adult; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy; D003278:Contraceptives, Oral, Hormonal / Q000009:adverse effects*; D003281:Contraceptives, Postcoital / Q000009:adverse effects*; D003282:Contraceptives, Postcoital, Hormonal / Q000009:adverse effects*; D004347:Drug Interactions; D004997:Ethinyl Estradiol / Q000009:adverse effects*; D019304:Ethinyl Estradiol-Norgestrel Combination; D005260:Female; D006801:Humans; D007654:Ketoconazole / Q000009:adverse effects* / Q000627:therapeutic use; D008599:Menstruation Disturbances / Q000139:chemically induced*; D009644:Norgestrel / Q000009:adverse effects*
D003278:Contraceptives, Oral, Hormonal; D003281:Contraceptives, Postcoital; D003282:Contraceptives, Postcoital, Hormonal; D009644:Norgestrel; D004997:Ethinyl Estradiol; D019304:Ethinyl Estradiol-Norgestrel Combination; D007654:Ketoconazole